Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of drugs shows promise for tough lung cancer

NCT ID NCT03819465

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether combining the immunotherapy durvalumab with other experimental drugs (danvatirsen, oleclumab) and/or chemotherapy can safely control stage IV non-small cell lung cancer. About 175 people who have not had prior treatment for metastatic disease will receive different drug combinations. The main goal is to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
durvalumab (an immunotherapy) combined with danvatirsen, oleclumab, and/or chemotherapy
What this could lead to
If successful, this could point toward new combination treatments that help control advanced lung cancer for longer.
What could go wrong
This is a very early (Phase 1) trial with only 175 participants, so results may not apply broadly. Side effects from combining multiple drugs are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

  • Research Site

    Iowa City, Iowa, 52242, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Edegem, 2650, Belgium

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Grudziądz, 86-300, Poland

  • Research Site

    Lodz, 90-302, Poland

  • Research Site

    Olsztyn, 10-357, Poland

  • Research Site

    Tomaszów Mazowiecki, 97-200, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wroclaw, 53-413, Poland

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Saint Petersburg, 191014, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 110-744, South Korea

  • Research Site

    Barcelona, 08025, Spain

  • Research Site

    Barcelona, 8003, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Kaohsiung City, 807, Taiwan

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.